Finally, the recent ESGO/ESTRO/ESP guidelines of endometrial carcinoma have approved MMRd/microsatellite instability as the selection criteria for second line anti-PD-1/PD-L1 based immune therapy with pembrolizumab. The gene discussed is CD274; the disease is endometrial carcinoma.